Results 151 to 160 of about 12,098 (189)

Case report: complete remission with crizotinib in ROS1 fusion-positive sinonasal mucosal melanoma. [PDF]

Front Oncol, 2022
Cao J, Yu Y, Zhou Y, Ji Q, Qian W, Jia D, Jin G, Qi Y, Li X, Li N, Li T, Fang M, Jin H.   +12 more
europepmc   +1 more source

Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancer. [PDF]

Clin Transl Med
Desilets A, Repetto M, Drilon A.
europepmc   +1 more source

Discovery of Oral Degraders of the ROS1 Fusion Protein with Potent Activity against Secondary Resistance Mutations. [PDF]

J Med Chem
Peng X, Guo S, Zheng S, Hossain A, Zhang C, Mottamal M, Skripnikova E, Ma P, Martinez-Carter K, Zhang Q, Abedin F, Huckaba T, Wang G.   +12 more
europepmc   +1 more source

Response to Entrectinib in Differentiated Thyroid Cancer With a ROS1 Fusion [PDF]

JCO Precision Oncology, 2017
Liu, Stephen V., Macke, Laura A., Colton, Bradley S., Imran, Sikandar S., Christiansen, Jason, Chow-Maneval, Edna, Hornby, Zachary, Multani, Pratik S.   +7 more
openaire   +2 more sources

Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report. [PDF]

Oncologist, 2021
Wang Y, Chen Z, Han X, Li J, Guo H, Shi J.   +5 more
europepmc   +1 more source

<i>ROS1</i> fusion-positive non-small cell lung cancer-repotrectinib as a new treatment option. [PDF]

Transl Cancer Res
Rothschild SI, Mauti LA.
europepmc   +1 more source

Molecular and Clinical characteristics of ROS1 Fusion Variants in ROS1-rearranged Cancers: A Defined Role of Fusion Partners and Breakpoints of ROS1

European Journal of Cancer
Ji-Seon Jeong, Yeokyeong Shin, Shinkyo Yoon, Deokhoon Kim, Josephina Sampson, Richard Bayliss, Jene Choi   +6 more
openaire   +1 more source

Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study. [PDF]

ESMO Open
Niho S, Goto Y, Toyozawa R, Daga H, Ohashi K, Takahashi T, Tanaka H, Sakakibara-Konishi J, Hattori Y, Morise M, Kodani M, Ikeda T, Izumi H, Matsumoto S, Yoh K, Nomura S, Goto K.   +16 more
europepmc   +1 more source

Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker. [PDF]

Clin Transl Med
Plum PS, Hess T, Bertrand D, Morgenstern I, Velazquez Camacho O, Jonas C, Alidousty C, Wagner B, Roessler S, Albrecht T, Becker J, Richartz V, Holz B, Hoppe S, Poh HM, Chia BKH, Chan CX, Pathiraja T, Teo AS, Marquardt JU, Khng A, Heise M, Fei Y, Thieme R, Klein S, Hong JH, Dima SO, Popescu I, Hoppe-Lotichius M, Buettner R, Lautem A, Otto G, Quaas A, Nagarajan N, Rozen S, Teh BT, Goeppert B, Drebber U, Lang H, Tan P, Gockel I, Schumacher J, Hillmer AM.   +42 more
europepmc   +1 more source

Reclassification of a spindle cell sarcoma after identification of a TFG-ROS1 fusion: A case demonstrating the clinical benefit of next-generation sequencing in sarcoma. [PDF]

Mol Genet Genomic Med
Lim JJ, Chen EY, Schaub SK, Wagner MJ.
europepmc   +1 more source